首页 > 最新文献

Eye最新文献

英文 中文
Myopic traction maculopathy in fovea-involved myopic chorioretinal atrophy. 近视眼脉络膜视网膜萎缩中的近视牵引性黄斑病变
IF 2.8 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-23 DOI: 10.1038/s41433-024-03366-w
Cheng-Yung Lee, Tso-Ting Lai, Ta-Ching Chen, Yi-Ting Hsieh, Tzyy-Chang Ho, Chang-Hao Yang, Chung-May Yang

Objectives: To assess the specific features of myopic traction maculopathy (MTM) in the context of myopic macular atrophy (MA). The evolution, surgical considerations, optimal surgical procedures, and results were studied.

Methods: Retrospective, consecutive cases collection was performed for highly myopic eyes with MA (category 4, the classification system of META-analysis for Pathologic Myopia). Eighty-seven eyes of 75 patients with MA were included. The characteristics and evolution of the MTM were analyzed. Surgical indications and outcomes were evaluated and specific surgical features and techniques were assessed.

Results: Approximately half (50.6%) of the cases with MA presented with various stages of MTM. The majority were maculoschisis with a lamellar macular hole (LMH) and were characterized by an O-shaped LMH, high outer retinal schisis, thin floor, and a high percentage of thickened epiretinal tissue. Half (50%) of them either displayed maculoschisis progression (61%) or developed into macular hole with retinal detachment (39%), and all received surgical intervention. The inverted ILM flap technique, with or without fovea-sparing ILM peeling, was the most frequently used surgical technique (78%). Complete traction relief was achieved in most cases (94%).

Conclusion: MA contributes to the specific configuration and evolution of MTM, and characteristic maculoschisis with LMH is a frequent presentation in MA patients. MHRD development and structural progression were two major reasons for surgical intervention. Vitrectomy with inverted ILM flap effectively stabilized the macular structure with few recurrences.

目的评估近视性黄斑萎缩(MA)背景下近视牵引性黄斑病变(MTM)的具体特征。方法:对高度近视黄斑萎缩(MA)病例进行回顾性、连续性病例收集:方法:对患有近视黄斑萎缩的高度近视眼(病理近视 META 分析分类系统中的第 4 类)进行回顾性连续病例收集。共纳入 75 名 MA 患者的 87 只眼睛。对 MTM 的特征和演变进行了分析。对手术适应症和结果进行了评估,并对具体的手术特征和技术进行了评估:结果:约一半(50.6%)的 MA 患者出现不同阶段的 MTM。大多数病例为黄斑裂孔伴片状黄斑孔(LMH),其特征为 O 型 LMH、高度外层视网膜裂孔、薄底板和高比例增厚的视网膜外组织。其中有一半(50%)的患者会出现黄斑裂孔进展(61%)或发展为黄斑裂孔伴视网膜脱离(39%),所有患者都接受了手术治疗。最常用的手术方法是倒置的ILM瓣技术,包括或不包括保留眼窝的ILM剥离(78%)。大多数病例(94%)的牵引完全缓解:结论:MA导致了MTM的特殊结构和演变,MA患者经常出现特征性黄斑变性伴LMH。MHRD的发展和结构性进展是手术干预的两个主要原因。倒置的ILM瓣玻璃体切除术有效地稳定了黄斑结构,复发率极低。
{"title":"Myopic traction maculopathy in fovea-involved myopic chorioretinal atrophy.","authors":"Cheng-Yung Lee, Tso-Ting Lai, Ta-Ching Chen, Yi-Ting Hsieh, Tzyy-Chang Ho, Chang-Hao Yang, Chung-May Yang","doi":"10.1038/s41433-024-03366-w","DOIUrl":"https://doi.org/10.1038/s41433-024-03366-w","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the specific features of myopic traction maculopathy (MTM) in the context of myopic macular atrophy (MA). The evolution, surgical considerations, optimal surgical procedures, and results were studied.</p><p><strong>Methods: </strong>Retrospective, consecutive cases collection was performed for highly myopic eyes with MA (category 4, the classification system of META-analysis for Pathologic Myopia). Eighty-seven eyes of 75 patients with MA were included. The characteristics and evolution of the MTM were analyzed. Surgical indications and outcomes were evaluated and specific surgical features and techniques were assessed.</p><p><strong>Results: </strong>Approximately half (50.6%) of the cases with MA presented with various stages of MTM. The majority were maculoschisis with a lamellar macular hole (LMH) and were characterized by an O-shaped LMH, high outer retinal schisis, thin floor, and a high percentage of thickened epiretinal tissue. Half (50%) of them either displayed maculoschisis progression (61%) or developed into macular hole with retinal detachment (39%), and all received surgical intervention. The inverted ILM flap technique, with or without fovea-sparing ILM peeling, was the most frequently used surgical technique (78%). Complete traction relief was achieved in most cases (94%).</p><p><strong>Conclusion: </strong>MA contributes to the specific configuration and evolution of MTM, and characteristic maculoschisis with LMH is a frequent presentation in MA patients. MHRD development and structural progression were two major reasons for surgical intervention. Vitrectomy with inverted ILM flap effectively stabilized the macular structure with few recurrences.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study. 西班牙抗击视网膜失明协会。报告 3:血管内皮生长因子抑制剂对新生血管性老年黄斑变性低视力眼的临床疗效。全国数据库研究。
IF 2.8 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-21 DOI: 10.1038/s41433-024-03322-8
Martín Puzo, Pilar Calvo-Perez, Francisco Bartol-Puyal, Jorge Sanchez-Monroy, Ruben Martin-Pinardel, Alba Parrado-Carrillo, Aina Moll-Udina, Carolina Bernal-Morales, Laura Sanchez-Vela, Laura Sararols-Ramsay, Gonzaga Garay-Aramburu, Carolina Arruabarrena, José García-Arumí, Maximino Abraldes, José María Ruiz-Moreno, Xavier Valldeperas, Daniel Velázquez-Villoria, José Juan Escobar-Barranco, Roberto Gallego-Pinazo, Marta S Figueroa, Marc Figueras-Roca, Daniel Barthelmes, Mark C Gillies, Ricardo P Casaroli-Marano, Javier Zarranz-Ventura

Objectives: To compare visual outcomes for low vision eyes (LVE) (<35 letters LogMAR or <20/200 Snellen) versus non-low vision eyes (NLVE) (>35 letters LogMAR or >20/200 Snellen) at the time of the first injection in a clinical practice setting.

Methods: Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!).

Results: 3138 eyes were included, 705 LVE and 2433 NLVE. The LVE group had the greatest VA gain (p < 0.001), at 12, 24, and 36 months (+15, +15, and +13 letters respectively). The proportion of patients with VA loss (-5 letters) differed between groups at 12, 24, and 36 and was significantly greater (p < 0.001) in NLVE. The proportion of patients with VA gain (+5 letters) was significantly higher (p < 0.001) in LVE in all timeframes. The proportions of LVE that still had VA ≤ 35 letters at 12, 24, and 36 months were 54%, 54%, and 57%. Conversely, 8%, 9%, and 8% of LVE achieved VA ≥ 70 letters at 12, 24, and 36 months. LVE received fewer intravitreal injections than NLVE throughout follow-up (6, 9, 12 vs 7, 11, 15).

Conclusion: Findings of this study support the need for ongoing therapy in patients with initial visual acuity less than 35 letters since sustained visual improvements can be achieved and maintained for the first 3 years of treatment.

目的:比较临床实践中低视能眼(LVE)首次注射时的视觉效果:比较低视力眼(LVE)(35 letters LogMAR 或 >20/200 Snellen)在临床实践中首次注射时的视觉效果:对多中心国家数据库中接受抗血管内皮生长因子(anti-VEGF)玻璃体内注射治疗的新生血管性年龄相关性黄斑变性(nAMD)患者进行分组分析,将其分为低视力眼(LVE)和低视力眼(NLVE)。使用经过验证的网络工具(Fight Retinal Blindness!)收集人口统计数据、基线和后续时间点(12、24 和 36 个月)的视力(VA)、注射次数和就诊数据:共纳入了 3138 只眼睛,其中 705 只为 LVE,2433 只为 NLVE。结果:共纳入 3138 只眼睛,其中 705 只为 LVE,2433 只为 NLVE:这项研究的结果支持了对初始视力低于 35 个字母的患者进行持续治疗的必要性,因为持续的视力改善可以在治疗的头 3 年中实现和保持。
{"title":"Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study.","authors":"Martín Puzo, Pilar Calvo-Perez, Francisco Bartol-Puyal, Jorge Sanchez-Monroy, Ruben Martin-Pinardel, Alba Parrado-Carrillo, Aina Moll-Udina, Carolina Bernal-Morales, Laura Sanchez-Vela, Laura Sararols-Ramsay, Gonzaga Garay-Aramburu, Carolina Arruabarrena, José García-Arumí, Maximino Abraldes, José María Ruiz-Moreno, Xavier Valldeperas, Daniel Velázquez-Villoria, José Juan Escobar-Barranco, Roberto Gallego-Pinazo, Marta S Figueroa, Marc Figueras-Roca, Daniel Barthelmes, Mark C Gillies, Ricardo P Casaroli-Marano, Javier Zarranz-Ventura","doi":"10.1038/s41433-024-03322-8","DOIUrl":"https://doi.org/10.1038/s41433-024-03322-8","url":null,"abstract":"<p><strong>Objectives: </strong>To compare visual outcomes for low vision eyes (LVE) (<35 letters LogMAR or <20/200 Snellen) versus non-low vision eyes (NLVE) (>35 letters LogMAR or >20/200 Snellen) at the time of the first injection in a clinical practice setting.</p><p><strong>Methods: </strong>Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!).</p><p><strong>Results: </strong>3138 eyes were included, 705 LVE and 2433 NLVE. The LVE group had the greatest VA gain (p < 0.001), at 12, 24, and 36 months (+15, +15, and +13 letters respectively). The proportion of patients with VA loss (-5 letters) differed between groups at 12, 24, and 36 and was significantly greater (p < 0.001) in NLVE. The proportion of patients with VA gain (+5 letters) was significantly higher (p < 0.001) in LVE in all timeframes. The proportions of LVE that still had VA ≤ 35 letters at 12, 24, and 36 months were 54%, 54%, and 57%. Conversely, 8%, 9%, and 8% of LVE achieved VA ≥ 70 letters at 12, 24, and 36 months. LVE received fewer intravitreal injections than NLVE throughout follow-up (6, 9, 12 vs 7, 11, 15).</p><p><strong>Conclusion: </strong>Findings of this study support the need for ongoing therapy in patients with initial visual acuity less than 35 letters since sustained visual improvements can be achieved and maintained for the first 3 years of treatment.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autosomal recessive bestrinopathy mimicking juvenile retinoschisis. 模仿幼年视网膜裂伤的常染色体隐性瞳孔病。
IF 2.8 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-20 DOI: 10.1038/s41433-024-03359-9
Siddhartha Rao B S, Rohan Chawla, Vinod Kumar
{"title":"Autosomal recessive bestrinopathy mimicking juvenile retinoschisis.","authors":"Siddhartha Rao B S, Rohan Chawla, Vinod Kumar","doi":"10.1038/s41433-024-03359-9","DOIUrl":"https://doi.org/10.1038/s41433-024-03359-9","url":null,"abstract":"","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of optical coherence tomography biomarkers in patients with non-neovascular age-related macular degeneration (AMD) converting to exudative AMD according to the status of the fellow eye. 根据同侧眼的状况,评估非血管性老年性黄斑变性(AMD)转化为渗出性AMD患者的光学相干断层扫描生物标志物。
IF 2.8 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-20 DOI: 10.1038/s41433-024-03357-x
Nicola Valsecchi, Stavan Shah, Arman Zarnegar, Anthony Tang, Shiva Yagobian, Luigi Fontana, Danilo Iannetta, Jay Chhablani

Objectives: To compare optical coherence tomography (OCT) biomarkers in eyes converting from non-neovascular (nnAMD) to exudative age-related macular degeneration (eAMD) based on the status of fellow eye.

Methods: Retrospective analysis of one year of pre-conversion data of fellow eyes of patients with nnAMD and eAMD which converted to eAMD, defined as converting eyes (CE) with fellow nnAMD and CE with fellow eAMD respectively. Demographics, best corrected visual acuity (BCVA), and OCT biomarkers including drusen type, iRORA/cRORA, subfoveal ellipsoid zone (SFEZ) disruption, central macular thickness (CMT), subfoveal choroidal thickness (SFCT), Haller vascular thickness (HVT) were evaluated. Chi-square and t-tests were employed, confidence interval of 95% and p < 0.05.

Results: 72 eyes of 72 patients were included: 31 CE with fellow nnAMD and 41 CE with fellow eAMD. Mean age was 81.8 ± 9.9 years, with 62.5% females. Subfoveal iRORA was more frequent in CE with fellow nnAMD (26%) compared to CE with fellow eAMD (6%) 44 weeks before conversion (p = 0.058). SFCT and HVT were higher in CE with fellow nnAMD compared to CE with fellow eAMD 19 weeks prior to conversion (213 ± 82 vs. 174 ± 63 µm, p = 0.052; 121 ± 44 vs. 104 ± 50 µm, p = 0.084 respectively). BCVA was significantly higher in CE with fellow eAMD compared to CE with fellow nnAMD every time frame (p < 0.05).

Conclusions: Although subtle distinctions, no significant differences were observed between the groups. Further research is needed to understand the influence of one eye's status on progression from nnAMD to eAMD in fellow eye.

研究目的根据同侧眼的状况,比较从非新生血管性黄斑变性(nnAMD)转化为渗出性年龄相关性黄斑变性(eAMD)的眼的光学相干断层扫描(OCT)生物标志物:方法:回顾性分析nnAMD和eAMD患者同侧眼转换为eAMD前一年的数据,分别定义为同侧眼为nnAMD的转换眼(CE)和同侧眼为eAMD的转换眼(CE)。研究人员评估了患者的人口统计学特征、最佳矫正视力(BCVA)和 OCT 生物标记物,包括眼底色素类型、iRORA/cRORA、眼底椭圆形区(SFEZ)破坏、黄斑中心厚度(CMT)、眼底脉络膜厚度(SFCT)和霍勒血管厚度(HVT)。采用卡方检验和 t 检验,置信区间为 95% 和 p 结果:共纳入 72 名患者的 72 只眼睛:其中,31 位 CE 同时患有 nnAMD,41 位 CE 同时患有 eAMD。平均年龄为 81.8 ± 9.9 岁,女性占 62.5%。与同为 eAMD 的 CE(6%)相比,同为 nnAMD 的 CE(26%)眼底 iRORA 在转换前 44 周更为常见(p = 0.058)。与患有 eAMD 的 CE 相比,患有 nnAMD 的 CE 在转换前 19 周的 SFCT 和 HVT 更高(分别为 213 ± 82 vs. 174 ± 63 µm,p = 0.052;121 ± 44 vs. 104 ± 50 µm,p = 0.084)。与患有同侧 eAMD 的 CE 相比,患有同侧 nnAMD 的 CE 在每个时间段的 BCVA 都明显较高(p 结论):尽管存在细微差别,但各组之间未观察到明显差异。要了解一只眼的状态对同侧眼从 nnAMD 发展到 eAMD 的影响,还需要进一步的研究。
{"title":"Assessment of optical coherence tomography biomarkers in patients with non-neovascular age-related macular degeneration (AMD) converting to exudative AMD according to the status of the fellow eye.","authors":"Nicola Valsecchi, Stavan Shah, Arman Zarnegar, Anthony Tang, Shiva Yagobian, Luigi Fontana, Danilo Iannetta, Jay Chhablani","doi":"10.1038/s41433-024-03357-x","DOIUrl":"https://doi.org/10.1038/s41433-024-03357-x","url":null,"abstract":"<p><strong>Objectives: </strong>To compare optical coherence tomography (OCT) biomarkers in eyes converting from non-neovascular (nnAMD) to exudative age-related macular degeneration (eAMD) based on the status of fellow eye.</p><p><strong>Methods: </strong>Retrospective analysis of one year of pre-conversion data of fellow eyes of patients with nnAMD and eAMD which converted to eAMD, defined as converting eyes (CE) with fellow nnAMD and CE with fellow eAMD respectively. Demographics, best corrected visual acuity (BCVA), and OCT biomarkers including drusen type, iRORA/cRORA, subfoveal ellipsoid zone (SFEZ) disruption, central macular thickness (CMT), subfoveal choroidal thickness (SFCT), Haller vascular thickness (HVT) were evaluated. Chi-square and t-tests were employed, confidence interval of 95% and p < 0.05.</p><p><strong>Results: </strong>72 eyes of 72 patients were included: 31 CE with fellow nnAMD and 41 CE with fellow eAMD. Mean age was 81.8 ± 9.9 years, with 62.5% females. Subfoveal iRORA was more frequent in CE with fellow nnAMD (26%) compared to CE with fellow eAMD (6%) 44 weeks before conversion (p = 0.058). SFCT and HVT were higher in CE with fellow nnAMD compared to CE with fellow eAMD 19 weeks prior to conversion (213 ± 82 vs. 174 ± 63 µm, p = 0.052; 121 ± 44 vs. 104 ± 50 µm, p = 0.084 respectively). BCVA was significantly higher in CE with fellow eAMD compared to CE with fellow nnAMD every time frame (p < 0.05).</p><p><strong>Conclusions: </strong>Although subtle distinctions, no significant differences were observed between the groups. Further research is needed to understand the influence of one eye's status on progression from nnAMD to eAMD in fellow eye.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cochrane corner: artificial intelligence for keratoconus. 科克伦角:人工智能治疗角膜炎。
IF 2.8 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-19 DOI: 10.1038/s41433-024-03347-z
Ethan Wen Wei Tiong, Su-Hsun Liu, Darren S J Ting
{"title":"Cochrane corner: artificial intelligence for keratoconus.","authors":"Ethan Wen Wei Tiong, Su-Hsun Liu, Darren S J Ting","doi":"10.1038/s41433-024-03347-z","DOIUrl":"https://doi.org/10.1038/s41433-024-03347-z","url":null,"abstract":"","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wet to dry, rapid progression of fibrosis in proliferative diabetic retinopathy after anti-VEGF 抗血管内皮生长因子(VEGF)治疗后,增殖性糖尿病视网膜病变的纤维化由湿变干、快速发展
IF 3.9 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-19 DOI: 10.1038/s41433-024-03351-3
Guangwei Yu, Yanhui Han, Donglin Wang
{"title":"Wet to dry, rapid progression of fibrosis in proliferative diabetic retinopathy after anti-VEGF","authors":"Guangwei Yu, Yanhui Han, Donglin Wang","doi":"10.1038/s41433-024-03351-3","DOIUrl":"https://doi.org/10.1038/s41433-024-03351-3","url":null,"abstract":"","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The shortcomings of China’s myopia control strategies 中国近视控制策略的不足之处
IF 3.9 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-19 DOI: 10.1038/s41433-024-03355-z
Renqi Luo

We read with interest the comment by Tuo et al. [1] which reviewed China’s policies on combating myopia and highlighted the positive contributions of these policies in addressing the myopia epidemic among Chinese children and adolescents. Undeniably, the Chinese government has achieved some success by implementing standardized, nationwide anti-myopia measures through various normative policies.

However, we observed that nearly all the policies mentioned in the comment advocate the practice of Chinese eye exercises. In some policies, schools are even mandated to conduct these exercises 1–2 times daily. In fact, since 1963, Chinese eye exercises have been implemented nationwide in primary and secondary schools. Despite their over 60-year history, there has never been strong evidence to support the effectiveness of these exercises in improving vision [2]. Despite the accumulating medical evidence, the practice of performing Chinese eye exercises in schools has persisted.

我们饶有兴趣地阅读了 Tuo 等人的评论[1],该评论回顾了中国的近视防治政策,并强调了这些政策在解决中国儿童和青少年近视问题方面的积极贡献。不可否认,中国政府通过各种规范性政策,在全国范围内实施标准化的防近视措施,取得了一定的成效。然而,我们注意到,评论中提到的几乎所有政策都提倡做眼保健操。有些政策甚至规定学校每天要做 1-2 次眼保健操。事实上,自 1963 年起,中国的眼保健操就开始在全国中小学推行。尽管中医眼保健操已有 60 多年的历史,但从未有强有力的证据支持其对改善视力的有效性[2]。尽管医学证据不断积累,但在学校做眼保健操的做法却一直存在。
{"title":"The shortcomings of China’s myopia control strategies","authors":"Renqi Luo","doi":"10.1038/s41433-024-03355-z","DOIUrl":"https://doi.org/10.1038/s41433-024-03355-z","url":null,"abstract":"<p>We read with interest the comment by Tuo et al. [1] which reviewed China’s policies on combating myopia and highlighted the positive contributions of these policies in addressing the myopia epidemic among Chinese children and adolescents. Undeniably, the Chinese government has achieved some success by implementing standardized, nationwide anti-myopia measures through various normative policies.</p><p>However, we observed that nearly all the policies mentioned in the comment advocate the practice of Chinese eye exercises. In some policies, schools are even mandated to conduct these exercises 1–2 times daily. In fact, since 1963, Chinese eye exercises have been implemented nationwide in primary and secondary schools. Despite their over 60-year history, there has never been strong evidence to support the effectiveness of these exercises in improving vision [2]. Despite the accumulating medical evidence, the practice of performing Chinese eye exercises in schools has persisted.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The carbon footprint of cataract surgery pathways in England: an observational study using administrative data 英格兰白内障手术路径的碳足迹:一项使用行政数据的观察性研究
IF 3.9 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-19 DOI: 10.1038/s41433-024-03356-y
Maria van-Hove, Hasina Begum, Manraj Phull, Jonathan Bhargava, Lydia Chang, Tim W. R. Briggs, William K. Gray

Background

The National Health Service (NHS) in England has set a target to be net zero for carbon emissions by 2045. The aim of this study was to investigate the estimated difference between the carbon footprint of the Getting It Right First Time (GIRFT) High Volume Low Complexity (HVLC) pathway for cataract surgery and current practice.

Methods

Retrospective analysis of administrative data. Data were extracted from the Hospital Episode Statistics database for all elective cataract surgery procedures conducted in England from 1st April 2021 to 31st March 2022.

Results

The England average carbon footprint was 100.0 kgCO2e (ranging from 74.8 kgCO2e – 128.0 kgCO2e depending on Integrated Care Board). Had all Integrated Care Boards adhered to the GIRFT HVLC pathway, then 17.5 kilotonsCO2e would have been saved in 2021–22. The main limitation of our study is that only key elements of the cataract surgery pathway were included in the analysis.

Conclusions

Even in a standardised healthcare pathway such as cataract surgery and within a publicly funded national healthcare system, significant differences in practice exist. With this paper we have demonstrated that tackling this unwarranted variation and adhering to the GIRFT HVLC pathway where possible has the potential to reduce the carbon footprint of cataract surgery.

背景英国国家医疗服务体系(NHS)设定了到 2045 年实现碳净零排放的目标。本研究旨在调查白内障手术 "第一次就做对"(GIRFT)高容量低复杂性(HVLC)路径的碳足迹与现行做法之间的估计差异。结果英格兰的平均碳足迹为 100.0 kgCO2e(根据综合护理委员会的不同,范围在 74.8 kgCO2e - 128.0 kgCO2e 之间)。如果所有综合医疗委员会都采用 GIRFT HVLC 途径,那么 2021-22 年将可节省 17.5 千吨 CO2e。结论即使是在白内障手术这样的标准化医疗途径中,即使是在政府资助的国家医疗系统中,也存在着显著的实践差异。本文表明,解决这种不必要的差异并尽可能地遵循 GIRFT HVLC 路径有可能减少白内障手术的碳足迹。
{"title":"The carbon footprint of cataract surgery pathways in England: an observational study using administrative data","authors":"Maria van-Hove, Hasina Begum, Manraj Phull, Jonathan Bhargava, Lydia Chang, Tim W. R. Briggs, William K. Gray","doi":"10.1038/s41433-024-03356-y","DOIUrl":"https://doi.org/10.1038/s41433-024-03356-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>The National Health Service (NHS) in England has set a target to be net zero for carbon emissions by 2045. The aim of this study was to investigate the estimated difference between the carbon footprint of the Getting It Right First Time (GIRFT) High Volume Low Complexity (HVLC) pathway for cataract surgery and current practice.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Retrospective analysis of administrative data. Data were extracted from the Hospital Episode Statistics database for all elective cataract surgery procedures conducted in England from 1st April 2021 to 31st March 2022.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The England average carbon footprint was 100.0 kgCO<sub>2</sub>e (ranging from 74.8 kgCO<sub>2</sub>e – 128.0 kgCO<sub>2</sub>e depending on Integrated Care Board). Had all Integrated Care Boards adhered to the GIRFT HVLC pathway, then 17.5 kilotonsCO<sub>2</sub>e would have been saved in 2021–22. The main limitation of our study is that only key elements of the cataract surgery pathway were included in the analysis.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Even in a standardised healthcare pathway such as cataract surgery and within a publicly funded national healthcare system, significant differences in practice exist. With this paper we have demonstrated that tackling this unwarranted variation and adhering to the GIRFT HVLC pathway where possible has the potential to reduce the carbon footprint of cataract surgery.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Royal College of Ophthalmologists’ National Ophthalmology Database study of cataract surgery: Report 17, a risk factor model for posterior capsule rupture 英国皇家眼科医学院国家眼科数据库白内障手术研究:报告 17:后囊破裂的风险因素模型
IF 3.9 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-19 DOI: 10.1038/s41433-024-03344-2
Peng Yong Sim, Paul H. J. Donachie, Alexander C. Day, John C. Buchan

Background/Objectives

To create a risk factor model for posterior capsule rupture (PCR) during cataract surgery.

Subjects/Methods

Eligible operations between 01/04/2016 and 31/03/2022 from centres supplying data to the UK national cataract audit with complete data including patients’ gender and age at surgery, anterior chamber depth (ACD) measurement and preoperative visual acuity (VA) were included. A logistic regression model was fitted to identify risk factors and calculate their odds ratios (OR) and 95% confidence intervals (CI) for PCR.

Results

This analysis included 961,208 cataract operations performed on 682,381 patients from 136 participating centres by 3198 surgeons. 9730 (1.01%) of surgeries were complicated by PCR. The median age was 75.7 and 76.7 years for first and second eye surgery respectively, and 5154 (53.0%) were female. The highest risk factors for PCR were less experienced trainee surgeon (OR 3.75, 95% CI 3.33–4.24, p < 0.001), pseudoexfoliation/phacodonesis (OR 3.47, 95% CI 3.05–3.94, p < 0.001), younger males (OR 3.05, 95% CI 2.23–4.16, p < 0.001) and brunescent/white/mature cataract (OR 2.41, 95% CI 2.24–2.60, p < 0.001). Other risk factors identified were glaucoma, worse preoperative VA, previous intravitreal therapy, high myopia, previous vitrectomy, systemic diabetes, diabetic retinopathy, amblyopia, older age, shallower ACD and inability to lie flat and cooperate.

Conclusion

Various surgical, patient and ocular factors increase the risk of PCR during cataract surgery. This risk factor model permits estimation of individualised risks for patients and allows risk-adjustment for surgeons to evaluate their PCR rates based on case complexity.

背景/目的建立白内障手术后囊破裂(PCR)的风险因素模型。研究对象/方法纳入2016年4月1日至2022年3月31日期间符合条件的手术,这些手术来自向英国国家白内障审计提供数据的中心,数据完整,包括患者的性别、手术年龄、前房深度(ACD)测量值和术前视力(VA)。该分析包括 136 个参与中心的 961 208 例白内障手术,由 3198 名外科医生为 682 381 名患者实施。9730例(1.01%)手术因 PCR 而变得复杂。第一次和第二次眼科手术的中位年龄分别为 75.7 岁和 76.7 岁,5154 名(53.0%)患者为女性。PCR的最高风险因素是经验较少的实习医生(OR 3.75,95% CI 3.33-4.24,p <0.001)、假性角膜剥脱/角膜松解(OR 3.47,95% CI 3.05-3.94,p <0.001)、年轻男性(OR 3.05,95% CI 2.23-4.16,p <0.001)和白发/白内障(OR 2.41,95% CI 2.24-2.60,p <0.001)。其他风险因素包括青光眼、术前视力较差、既往接受过玻璃体内治疗、高度近视、既往接受过玻璃体切除术、全身性糖尿病、糖尿病视网膜病变、弱视、年龄较大、ACD 较浅以及无法平躺和合作。该风险因素模型可估算出患者的个体化风险,并根据病例的复杂程度对外科医生进行风险调整,以评估其 PCR 发生率。
{"title":"The Royal College of Ophthalmologists’ National Ophthalmology Database study of cataract surgery: Report 17, a risk factor model for posterior capsule rupture","authors":"Peng Yong Sim, Paul H. J. Donachie, Alexander C. Day, John C. Buchan","doi":"10.1038/s41433-024-03344-2","DOIUrl":"https://doi.org/10.1038/s41433-024-03344-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background/Objectives</h3><p>To create a risk factor model for posterior capsule rupture (PCR) during cataract surgery.</p><h3 data-test=\"abstract-sub-heading\">Subjects/Methods</h3><p>Eligible operations between 01/04/2016 and 31/03/2022 from centres supplying data to the UK national cataract audit with complete data including patients’ gender and age at surgery, anterior chamber depth (ACD) measurement and preoperative visual acuity (VA) were included. A logistic regression model was fitted to identify risk factors and calculate their odds ratios (OR) and 95% confidence intervals (CI) for PCR.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>This analysis included 961,208 cataract operations performed on 682,381 patients from 136 participating centres by 3198 surgeons. 9730 (1.01%) of surgeries were complicated by PCR. The median age was 75.7 and 76.7 years for first and second eye surgery respectively, and 5154 (53.0%) were female. The highest risk factors for PCR were less experienced trainee surgeon (OR 3.75, 95% CI 3.33–4.24, <i>p</i> &lt; 0.001), pseudoexfoliation/phacodonesis (OR 3.47, 95% CI 3.05–3.94, <i>p</i> &lt; 0.001), younger males (OR 3.05, 95% CI 2.23–4.16, <i>p</i> &lt; 0.001) and brunescent/white/mature cataract (OR 2.41, 95% CI 2.24–2.60, <i>p</i> &lt; 0.001). Other risk factors identified were glaucoma, worse preoperative VA, previous intravitreal therapy, high myopia, previous vitrectomy, systemic diabetes, diabetic retinopathy, amblyopia, older age, shallower ACD and inability to lie flat and cooperate.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Various surgical, patient and ocular factors increase the risk of PCR during cataract surgery. This risk factor model permits estimation of individualised risks for patients and allows risk-adjustment for surgeons to evaluate their PCR rates based on case complexity.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: ALTAIR study 信息图:玻璃体内阿弗利百普治疗和延长方案在渗出性年龄相关性黄斑变性中的疗效和安全性:ALTAIR研究
IF 3.9 3区 医学 Q1 OPHTHALMOLOGY
Eye
Pub Date : 2024-09-19 DOI: 10.1038/s41433-024-03336-2
Ishani Barai, Rashmi G. Mathew, Sobha Sivaprasad, Christin Henein

Reference to original article:

Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020 Mar;37(3):1173-1187.

原文参考:Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators.玻璃体内阿弗利百普治疗和延长方案对渗出性年龄相关性黄斑变性的疗效和安全性:ALTAIR:一项随机对照试验的 52 周和 96 周结果。Adv Ther.2020年3月;37(3):1173-1187。
{"title":"Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: ALTAIR study","authors":"Ishani Barai, Rashmi G. Mathew, Sobha Sivaprasad, Christin Henein","doi":"10.1038/s41433-024-03336-2","DOIUrl":"https://doi.org/10.1038/s41433-024-03336-2","url":null,"abstract":"<p>Reference to original article:</p><p>Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020 Mar;37(3):1173-1187.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Eye
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1